Bausch Health Companies | VRX - Interest Expense On Debt


Bausch Health Companies reported $402M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Amgen USD 95.64B 94.98B Jun/2026
ANI Pharmaceuticals USD 3.64M 775K Jun/2026
Aurora Cannabis CAD 230K 1.88M Mar/2026
Bausch Health Companies USD 402M 5M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 407M 4M Jun/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Danaher USD 135M 28M Sep/2026
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 247M 7M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Pacira USD 3.62M 77K Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 13.94M 2.52M Jun/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Zoetis USD 61M 1000K Jun/2026